EMS Group: 2025 Annual Results on the Rise

EMS Group reported revenue growth of 11% in 2025, reaching €49.9 million. EBITDA increased by 23% to €5.4 million, with a margin of 10.8%. Net income rose by €1.3 million to €1.8 million. This performance was driven by growth in radiology and bone densitometry, with strong performance in North America and the Middle East.

R&D efforts continued, particularly for the development of the ONYX mobile radiology unit. Sales were split between private label (51%) and white label (49%). The financial situation remained under control with shareholders' equity of €12.1 million and cash reserves of €5.8 million. Net debt amounted to €9.0 million.

For 2026, despite current challenges, EMS Group anticipates sustained growth, based on international markets, especially in Ukraine and North America.